Safety and Health in Biomass Production, Transportation, and Storage: A Commentary Based on the Biomass and Biofuels Session at the 2013 North American Agricultural Safety Summit

There is significant interest in biomass production ranging from government agencies to the private sector, both inside and outside of the traditional production agricultural setting. This interest has led to an increase in the development and production of biomass crops. Much of this effort has focused on specific segments of the process, and more specifically on the mechanics of these individual segments. From a review of scientific literature, it is seen that little effort has been put into identifying, classifying and preventing safety hazards in on-farm biomass production systems. This commentary describes the current status of the knowledge pertaining to health and safety factors of biomass production and storage in the US and identifies areas of standards development that the biomass industry needs from the agricultural safety and health community

Evaluation of Toxicity Analysis for Foundry Sand Specifications

Byproducts from many industries have the potential to be used as construction materials, but some means is required to determine if the material is environmentally benign. Foundry sands are produced in many states and can be useful as in transportation projects. However, INDOT currently requires the use of the MICROTOX test to assess the potential toxicity of the sands, and this requirement is viewed as an unnecessary impediment by the producers of foundry sands and is a requirement not encountered in other states. Therefore, the goal of this project was to review current requirements for testing of recycled materials, determine the availability of MICROTOX testing, and to make recommendations concerning the continued use of MICROTOX as an assessment tool. Strictly from viewpoint of environmental protection, the inclusion of Microtox makes sense. The test has the sensitivity to detect potentially toxic agents in recycled sand that might escape chemical analysis. The test, therefore, provides a layer of assurance that otherwise would be absent. From the perspective of the foundry industry, the Microtox test is an unneeded hurdle that could potentially block the beneficial use of spent foundry sand. Cost is one consideration, but the lack of local analytical facilities for the Microtox is particularly troublesome. Our recommendation is that the Microtox test be retained by INDOT, but we suggest the following: a) Minimize the number of samples of foundry sand that must be tested possibly by reducing the frequency of sampling and testing. b) A consistent, readily available laboratory needs to be established to ensure rapid turn around of analyses and reduced costs. Currently, the demand is low and some dedicated equipment is needed to perform the test. One of the potential outcomes of this project discussed during the negotiations for this project was a possible follow-up project in which we would investigate the modifications to the bioassay. This might include exploring alternatives to Microtox or simplifications of the Microtox test. We remain open to this possibility, but from the scientific point of view, such a follow-up may not be necessary. Of all the bioassays we reviewed, Microtox seemed to be the most widely used (though not for foundry sands), and we found no evidence that other bioassays were being offered routinely at commercial labs

Polens Politik in der Krise?

In dieser vorliegenden Forschungsarbeit soll der Versuch unternommen werden, die polnischen Parteien anhand ihrer Organisationsstruktur zu analysieren, um damit eine Aussage über den allgemeinen Zustand der repräsentativen Demokratie in Polen tätigen zu können. Das polnische Parteiensystem hat mit dem Parteiengesetz 1997 den Weg einer langsamen Stabilisierung eingeschlagen. Seit dem (vorläufigen) Verschwinden der „Linken“ von der politischen Bühne im Jahre 2005 konnten sich zwei Parteien, die PO („Bürgerplattform“) und PiS („Recht und Gerechtigkeit“), als dominierende Kräfte behaupten. Diese können aufgrund ihrer Organisationsstruktur als ein Repräsentantinnen eines „neuen“ Parteityps bezeichnet werden. Sie zeichnen sich durch ihre Abhängigkeit vom Staat, ihre geringe Mitgliederzahl und eine verstärkte Professionalisierung aus. Pointiert könnten sie auch als Staatsparteien bezeichnet werden. Der „neue“ Parteityp kann vor allem als eine Reaktion auf die besonderen historischen Verhältnisse Polens gesehen werden. Mit Blick auf die repräsentative Demokratie kann festgehalten werden, dass der „neue“ Parteityp die ihm zugedachten Funktionen grundsätzlich erfüllen kann. Es gelingt ihm aber nicht mehr, die BürgerInnen für Wahlen zu mobilisieren, womit ein Legitimitätsverlust der Parteien im Speziellen, aber auch der repräsentativen Demokratie im Allgemeinen, einher geht. Die geringe Wahlbeteiligung ist aber nicht als ein spezifisch polnisches Problem zu sehen, vielmehr muss diese angesichts rückläufiger Zahlen bei der Wahlbeteiligung in den „alten“ europäischen Demokratien als ein europaweites Problem gesehen werden

Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay.

Analysis of cell-free DNA using next-generation sequencing (NGS) is a powerful tool for the detection/monitoring of alterations present in circulating tumor DNA (ctDNA). Plasma extracted from 171 patients with a variety of cancers was analyzed for ctDNA (54 genes and copy number variants (CNVs) in three genes (EGFR, ERBB2 and MET)). The most represented cancers were lung (23%), breast (23%), and glioblastoma (19%). Ninety-nine patients (58%) had at least one detectable alteration. The most frequent alterations were TP53 (29.8%), followed by EGFR (17.5%), MET (10.5%), PIK3CA (7%), and NOTCH1 (5.8%). In contrast, of 222 healthy volunteers, only one had an aberration (TP53). Ninety patients with non-brain tumors had a discernible aberration (65% of 138 patients; in 70% of non-brain tumor patients with an alteration, the anomaly was potentially actionable). Interestingly, nine of 33 patients (27%) with glioblastoma had an alteration (6/33 (18%) potentially actionable). Overall, sixty-nine patients had potentially actionable alterations (40% of total; 69.7% of patients (69/99) with alterations); 68 patients (40% of total; 69% of patients with alterations), by a Food and Drug Administration (FDA) approved drug. In summary, 65% of diverse cancers (as well as 27% of glioblastomas) had detectable ctDNA aberration(s), with the majority theoretically actionable by an approved agent

SMAD3 contributes to ascending aortic dilatation independent of transforming growth factor-beta in bicuspid and unicuspid aortic valve disease

We sought to determine whether there are differences in transforming growth factor-beta (TGFß) signaling in aneurysms associated with bicuspid (BAV) and unicuspid (UAV) aortic valves versus normal aortic valves. Ascending aortic aneurysms are frequently associated with BAV and UAV. The mechanisms are not yet clearly defined, but similarities to transforming growth factor-beta TGFß vasculopathies (i.e. Marfan, Loeys-Dietz syndromes) are reported. Non-dilated (ND) and aneurysmal (D) ascending aortic tissue was collected intra-operatively from individuals with a TAV (N = 10ND, 10D), BAV (N = 7ND, 8D) or UAV (N = 7ND, 8D). TGFß signaling and aortic remodeling were assessed through immuno-assays and histological analyses. TGFß1 was increased in BAV/UAV-ND aortas versus TAV (P = 0.02 and 0.04, respectively). Interestingly, TGFß1 increased with dilatation in TAV (P = 0.03) and decreased in BAV/UAV (P = 0.001). In TAV, SMAD2 and SMAD3 phosphorylation (pSMAD2, pSMAD3) increased with dilatation (all P = 0.04) and with TGFß1 concentration (P = 0.04 and 0.03). No relationship between TGFß1 and pSMAD2 or pSMAD3 was observed for BAV/UAV (all P > 0.05). pSMAD3 increased with dilatation in BAV/UAV aortas (P = 0.01), whereas no relationship with pSMAD2 was observed (P = 0.56). Elastin breaks increased with dilatation in all groups (all P < 0.05). In TAV, elastin degradation correlated with TGFß1, pSMAD2 and pSMAD3 (all P < 0.05), whereas in BAV and UAV aortas, elastin degradation correlated only with pSMAD3 (P = 0.0007). TGFß signaling through SMAD2/SMAD3 contributes to aortic remodeling in TAV, whereas TGFß-independent activation of SMAD3 may underlie aneurysm formation in BAV/UAV aortas. Therefore, SMAD3 should be further investigated as a therapeutic target against ascending aortic dilatation in general, and particularly in BAV/UAV patients

Modules for Experiments in Stellar Astrophysics (MESA): Convective Boundaries, Element Diffusion, and Massive Star Explosions

We update the capabilities of the software instrument Modules for Experiments in Stellar Astrophysics (MESA) and enhance its ease of use and availability. Our new approach to locating convective boundaries is consistent with the physics of convection, and yields reliable values of the convective core mass during both hydrogen and helium burning phases. Stars with $M<8\,{\rm M_\odot}$ become white dwarfs and cool to the point where the electrons are degenerate and the ions are strongly coupled, a realm now available to study with MESA due to improved treatments of element diffusion, latent heat release, and blending of equations of state. Studies of the final fates of massive stars are extended in MESA by our addition of an approximate Riemann solver that captures shocks and conserves energy to high accuracy during dynamic epochs. We also introduce a 1D capability for modeling the effects of Rayleigh-Taylor instabilities that, in combination with the coupling to a public version of the STELLA radiation transfer instrument, creates new avenues for exploring Type II supernovae properties. These capabilities are exhibited with exploratory models of pair-instability supernova, pulsational pair-instability supernova, and the formation of stellar mass black holes. The applicability of MESA is now widened by the capability of importing multi-dimensional hydrodynamic models into MESA. We close by introducing software modules for handling floating point exceptions and stellar model optimization, and four new software tools -- MESAWeb, MESA-Docker, pyMESA, and mesastar.org -- to enhance MESA's education and research impact.Comment: 64 pages, 61 figures; Accepted to AAS Journal

Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies.

PurposeTo date, evidence for tissue epidermal growth factor receptor (EGFR) overexpression as a biomarker for anti-EGFR therapies has been weak. We investigated the genomic landscape of EGFR amplification in blood-derived cell-free tumor DNA (cfDNA) across diverse cancers and the role of anti-EGFR therapies in achieving response.MethodsWe assessed EGFR amplification status among 28,584 patients with malignancies evaluated by clinical-grade next-generation sequencing (NGS) of blood-derived cfDNA (54- to 73-gene panel). Furthermore, we curated the clinical characteristics of 1,434 patients at the University of California San Diego who had cfDNA testing by this NGS test.ResultsOverall, EGFR amplification was detected in cfDNA from 8.5% of patients (2,423 of 28,584), most commonly in colorectal (16.3% [458 of 2,807]), non-small-cell lung (9.0% [1,096 of 12,197]), and genitourinary cancers (8.1% [170 of 2,104]). Most patients had genomic coalterations (96.9% [95 of 98]), frequently involving genes affecting other tyrosine kinases (72.4% [71 of 98]), mitogen-activated protein kinase cascades (56.1% [55 of 98]), cell-cycle-associated signals (52.0% [51 of 98]), and the phosphoinositide 3-kinase pathway (35.7% [35 of 98]). EGFR amplification emerged in serial cfDNA after various anticancer therapies (n = 6), including checkpoint inhibitors (n = 4), suggesting a possible role for these amplifications in acquired resistance. Nine evaluable patients with EGFR amplification were treated with anti-EGFR-based regimens; five (55.6%) achieved partial responses, including three patients whose tissue NGS lacked EGFR amplification.ConclusionEGFR amplification was detected in cfDNA among 8.5% of 28,584 diverse cancers. Most patients had coexisting alterations. Responses were observed in five of nine patients who received EGFR inhibitors. Incorporating EGFR inhibitors into the treatment regimens of patients harboring EGFR amplification in cfDNA merits additional study

A comprehensive radial velocity error budget for next generation Doppler spectrometers

We describe a detailed radial velocity error budget for the NASA-NSF Extreme Precision Doppler Spectrometer instrument concept NEID (NN-explore Exoplanet Investigations with Doppler spectroscopy). Such an instrument performance budget is a necessity for both identifying the variety of noise sources currently limiting Doppler measurements, and estimating the achievable performance of next generation exoplanet hunting Doppler spectrometers. For these instruments, no single source of instrumental error is expected to set the overall measurement floor. Rather, the overall instrumental measurement precision is set by the contribution of many individual error sources. We use a combination of numerical simulations, educated estimates based on published materials, extrapolations of physical models, results from laboratory measurements of spectroscopic subsystems, and informed upper limits for a variety of error sources to identify likely sources of systematic error and construct our global instrument performance error budget. While natively focused on the performance of the NEID instrument, this modular performance budget is immediately adaptable to a number of current and future instruments. Such an approach is an important step in charting a path towards improving Doppler measurement precisions to the levels necessary for discovering Earth-like planets.Comment: 20 pages, 12 figures, published in Proc. of SPIE Astronomical Telescopes + Instrumentation 201

Bioavailability of cerium oxide nanoparticles to Raphanus sativus L. in two soils.

Cerium oxide nanoparticles (CeO2 NP) are a common component of many commercial products. Due to the general concerns over the potential toxicity of engineered nanoparticles (ENPs), the phytotoxicity and in planta accumulation of CeO2 NPs have been broadly investigated. However, most previous studies were conducted in hydroponic systems and with grain crops. For a few studies performed with soil grown plants, the impact of soil properties on the fate and transport of CeO2 NPs was generally ignored even though numerous previous studies indicate that soil properties play a critical role in the fate and transport of environmental pollutants. The objectives of this study were to evaluate the soil fractionation and bioavailability of CeO2 NPs to Raphanus sativus L (radish) in two soil types. Our results showed that the silty loam contained slightly higher exchangeable fraction (F1) of cerium element than did loamy sand soil, but significantly lower reducible (F2) and oxidizable (F3) fractions as CeO2 NPs concentration increased. CeO2 NPs associated with silicate minerals or the residue fraction (F4) dominated in both soils. The cerium concentration in radish storage root showed linear correlation with the sum of the first three fractions (r(2) = 0.98 and 0.78 for loamy sand and silty loam respectively). However, the cerium content in radish shoots only exhibited strong correlations with F1 (r(2) = 0.97 and 0.89 for loamy sand and silty loam respectively). Overall, the results demonstrated that soil properties are important factors governing the distribution of CeO2 NPs in soil and subsequent bioavailability to plants